|Bid||128.10 x 100|
|Ask||128.20 x 100|
|Day's Range||127.50 - 130.60|
|52 Week Range||37.05 - 136.85|
|PE Ratio (TTM)||-17.51|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||116.47|
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed Mary Lynne Hedley, Ph.D.
Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.
NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Dow Jones Industrial Average closed at a new record high for the third consecutive session on the strength of Boeing and United Technologies, while ...